FDA has approved Perrigo Company’s abbreviated new drug application for a generic version of clindamycin phosphate and benzoyl peroxide 1.2%/5% gel (Duac Gel, Stiefel Laboratories), the company recently announced in a statement. The gel is indicated for the topical treatment of inflammatory acne vulgaris.
FDA has approved Perrigo Company’s abbreviated new drug application for a generic version of clindamycin phosphate and benzoyl peroxide 1.2%/5% gel (Duac Gel, Stiefel Laboratories), the company recently announced in a statement. The gel is indicated for the topical treatment of inflammatory acne vulgaris.
Photo courtesy of Perrigo Company
“We’re pleased to bring this new topical product to market and continue to focus on our mission of making healthcare more accessible and affordable for consumers,” said Joseph C. Papa, Perrigo’s chairman, president, and CEO.
The company has begun shipment of the gel.
This treatment is contraindicated in people with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.